Research
FORUM TRANSCRIPT

Oncocyte – Molecular Diagnostics Market – Q1 2022 Update & Product Overview

  • Multi Asset
  • Healthcare
  • Global
PREMIUM

Specialist

Former VP at Oncocyte Corp

Agenda

  • Molecular diagnostics market trends and developments, highlighting Oncocyte (NASDAQ: OCX)
  • Product assessment – DetermaRx, DetermaIO, DetermaTx and DetermaCNI
  • Commercialisation capabilities for Oncocyte’s diagnostics products, potential supply chain disruptions and third-party reimbursement dynamics
  • Growth expectations and post-coronavirus outlook

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo